Onco Wiki / Régime

Capecitabine palliative monotherapy (CRC ECOG 3-4, BSC-adjacent low-intensity)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

ComposantesDRUG-CAPECITABINE
IDREG-CAPECITABINE-PALLIATIVE
TypeProtocole thérapeutique
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025

Notes

In ECOG 3-4 mCRC patients where full doublet (FOLFOX/CapOx) or triplet (FOLFIRINOX) is not feasible due to performance status, comorbidity burden, or patient preference, single-agent capecitabine offers a low-toxicity oral option that preserves quality of life while providing modest disease control (mPFS ~4-6 mo in unselected populations; longer in MSS / well-differentiated tumours). Avoids IV access requirements and reduces clinic burden. Discuss explicitly with patient + family that the goal is symptom-balance, not life-prolongation in any meaningful sense — this regimen is BSC-adjacent and the boundary between treatment and BSC is fluid. Co-enrol palliative care early. DPYD pre-screening strongly recommended (CPIC) — DPYD deficiency causes severe-fatal toxicity.

Utilisé par

Indication

Protocole thérapeutique